Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Abstract Background The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. Methods Re...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho-Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung-Sook Lee, Kengo Takeuchi, Dong-Yeop Shin, Cheolwon Suh, Won Seog Kim
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2019-11-01
Cyfres:	BMC Cancer
Pynciau:	Hodgkin lymphoma Mediastinal large B-cell lymphoma JAK2 Ruxolitinib
Mynediad Ar-lein:	http://link.springer.com/article/10.1186/s12885-019-6303-z
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!